Current Report Filing (8-k)
March 04 2014 - 6:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): March 4, 2014
Amarin Corporation plc
(Exact name of registrant as specified in its charter)
|
|
|
|
|
England and Wales |
|
0-21392 |
|
Not applicable |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
|
|
|
2 Pembroke House, Upper Pembroke Street 28-32,
Dublin 2, Ireland |
|
Not applicable |
(Address of principal executive offices) |
|
(Zip Code) |
Registrants telephone number, including area code: +353 1 6699 020
Not Applicable
Former
name or former address, if changed since last report
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On March 4, 2014, Amarin Pharmaceuticals Ireland Limited, a wholly owned subsidiary
of Amarin Corporation plc (Amarin), filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc., a Delaware corporation, and its parent company, AstraZeneca Pharmaceuticals LP.
The suit seeks injunctive relief and monetary damages for infringement of Amarins U.S. Patent No. 8,663,662 (the Patent), which was issued by the United States Patent and Trademark Office today. The complaint alleges
infringement of the Patent arising from the expected launch of EpanovaTM in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition
that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights.
Patent litigation is a time-consuming and costly process. There can be no guarantee that Amarin will be successful in enforcing the Patent or that the Patent
will not be successfully challenged and invalidated. Even if Amarin is successful in enforcing the Patent, the process could take years to reach conclusion.
Forward-looking statements
This Current Report on Form
8-K contains forward-looking statements, including statements about Amarins plan to pursue the litigation vigorously and aggressively protect its intellectual property rights, whether Amarin will be successful in enforcing the Patent, the
patent litigation process generally and whether Amarin will obtain the remedies sought. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual
results to differ materially from those described or projected herein include the following: events that could interfere with the continued validity or enforceability of the Patent; Amarins ability generally to successfully enforce patent
claims against third parties; Amarins decisions to devote sufficient resources to the above-described enforcement action; and uncertainties associated generally with litigation. A further list and description of these risks, uncertainties and
other risks associated with an investment in Amarin can be found in Amarins filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K. Existing and prospective investors are cautioned not to
place undue reliance on these forward-looking statements, which speak only as of the date hereof.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Date: March 4, 2014 |
|
|
|
Amarin Corporation plc |
|
|
|
|
|
|
|
|
By: |
|
/s/ John Thero |
|
|
|
|
|
|
John Thero |
|
|
|
|
|
|
President and Chief Executive Officer |
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024